Company intelligence / Profile preview

Axter Therapeutics

Beijing, Beijing, Chinacenterwatch.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Axter Therapeutics is a China-based biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. Its lead asset, AXT‑1003, is an oral small molecule EZH2 degrader currently in Phase 1 clinical trials for advanced malignancies and lymphomas. The compound was licensed from Novartis. Early-stage results are focused on safety, pharmacokinetics, and preliminary anti-tumor activity; no efficacy data has been published yet.

Therapeutic areas: Oncology
Modalities: Small moleculesTargeted protein degraders
Industry: Biotech

Drug pipeline

5 assets

AXT-1003

4 more assets in the full pipeline.

Request access →

Partnerships

Novartis – licensing agreement for global development/commercialization rights to AXT‑1003.

Beyond the preview

Go deeper on Axter Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axter Therapeutics.

Explore the full profile